参考文献/References:
[1] Georgoulias P, Tzavara C, Demakopoulous N, et al. Incremental prognostic value of 99mTc-tetrofosmin myocardial SPECT after percutaneous coronary intervention. Ann Nucl Med, 2008, 22(10):899-909.
[2] Alexiou GA, Tsiouris S, Kyritsis AP, et al. 99mTc-Tetrofosmin SPECT for the detection of glioma recurrence. Eur J Nucl Med Mol Imaging, 2008, 35(8):1571-1572.
[3] Spanu A, Cottu P, Manca A, et al. Scintimammography with dedicated breast camera in unifocal and multifocal/multicentric primary breast cancer detection:a comparative study with SPECT. Int J Oncol, 2007, 31(2):369-377.
[4] 陈慧玲,白海.肿瘤多药耐药的研究进展.临床肿瘤学杂志,2008,13(5):475-477.
[5] Abaan OD, Mutlu PK, Baran Y, et al. Muhidrug resistance mediated by MRPI gene overexpression in breast cancer patients. Cancer Invest, 2009, 27(2):201-205.
[6] Haslam IS, Jones K, Coleman T, et al. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol, 2008, 76(7):850-861.
[7] Takahashi K, Shibata T, Oba T, et al. Muhidrug-resistance-associated protein plays a protective role in menadione-induced oxidative stress in endothelial cells. Life Sci, 2009, 84(7-8):211-217.
[8] Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin Exp hnmunol, 2009, 155(2):239-248.
[9] Schmidt M, Teitge M, Castillo ME, et al. Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents. Arch Pharm(Weinhemin), 2008, 341(10):624-638.
[10] Morschhauser F, Zinzani PL, Burgess M, et al. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar. 3HC1 trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma, 2007, 48(4):708-715.
[11] Bihorel S, Camenisch G, Lemaire M, et al. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res, 2007, 24(9):1720-1728.
[12] Carlson RW, O’Neill AM, Goldstein L J, et al. A pilot phase II trial of valspodar modulation of multidmg resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195):a triat of the Eastern Cooperative Oncology Group. Cancer Invest, 2006, 24(7):677-681.
[13] Péréz-Tomás. Multidrug resistance:retrospect and prospects in anti-cancer drug treatment. Curr Med Chem, 2006, 13(16):1859-1876.
[14] Utsunomiya K, Ballinger JR, Piquette-Miller M, et al. Comparison of the accumulation and efflux kinetics of technetium-99msestamibi and technetium-99mtetrofosmin in an MRP-expressing tumor cell line. Eur J Nucl Med, 2000, 27(12):1786-1792.
[15] Dorajoo R, Pereira BP, Yu Z, et al. Role of multi-drug resistanceassociated protein-1 transporter in statin-induced myopathy. Life Sci, 2008, 82(15-16):823-830.
[16] Lewis-Wambi JS, Kim HR, Wambi C, et al. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res, 2008, 10(6):R104.
[17] Bankstahl JP, Kuntner C, Abrahim A, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med, 2008, 49(8):1328-1335.
[18] Kurdziel KA, Kalen, JD, Hirsch JI, et al. Imaging muhidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol, 2007, 34(7):823-831.
[19] Yang A, Xue J, Li X, et al. Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glyeoprotein expression in lung cancer. Nucl Med Commun, 2007, 28(9):696-703.
[20] Burak Z, Moretti JL, Ersoy O, et al. 99mFc-MIBI imaging as a predictor of therapy respose in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med, 2003, 44(9):1394-1401.
[21] Elhendy A, Schinkel AF, van Domberg RT, et al. Non-invasive diagnosis of in stent stenosis by stress 99m technetium tetrofosmin myocardial perfusion imaging. Int J Cardiovasc Imaging, 2006, 22(5):657-662.
[22] Younès A, Songadele JA, Maublant J, et al. Mechanism of uptake of technetium-tetrofosmin. II:Uptake into isolated adult rat heart mitochondria. J Nucl Cardiol, 1995, 2(4):327-333.
[23] Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of muhidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res,1993, 53(5):977-984.
[24] Ballinger JR, Bannerman J, Boxen I, et al. Technetium-99m-tetrofosmin as a substrate for P-glyeoprotein:in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med, 1996, 37(9):1578-1582.
[25] Liu Z, Stevenson GD, Barrett HH, et al. Imaging recognition of inhibition of multidrug resistance in human breast eaneer xenografts using 99mTc-labeled sestamibi and tetrofosmin.Nncl Med Biol, 2005, 32(6):573-583.
[26] Chen WS, Luker KE, Dahlheimer JL, et al. Effects of MDR1 and MDR3 P-glycoproteins, MRPI, and BCRP/MXR/ABCP on the transport of 99mTc-tetrofosmin. Biochem Pharmacol, 2000, 60(3):413-426.
[27] Soderlund V, Jonsson C, Bauer HC, et al. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med,1997, 38(5):682-686.
[28] Mansi L, Rambaldi PF, Cuccurullo V, et al. Diagnostic and prognostic role of 99mTc-tetrofosmin in breast cancer. Q J Nutl Med, 1997, 41(3):239-250.
[29] Sun SS, Hsieh JF, Tsai SC, et al. Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance. Anticancer Res, 2000, 20(3A):1467-1470.